Haemonetics Statistics
Total Valuation
Haemonetics has a market cap or net worth of $2.77 billion. The enterprise value is $3.65 billion.
Important Dates
The last earnings date was Thursday, May 7, 2026, before market open.
| Earnings Date | May 7, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Haemonetics has 46.47 million shares outstanding. The number of shares has decreased by -6.66% in one year.
| Current Share Class | 46.47M |
| Shares Outstanding | 46.47M |
| Shares Change (YoY) | -6.66% |
| Shares Change (QoQ) | -1.62% |
| Owned by Insiders (%) | 1.13% |
| Owned by Institutions (%) | 96.26% |
| Float | 45.93M |
Valuation Ratios
The trailing PE ratio is 29.05 and the forward PE ratio is 11.41. Haemonetics's PEG ratio is 1.00.
| PE Ratio | 29.05 |
| Forward PE | 11.41 |
| PS Ratio | 2.00 |
| Forward PS | 1.91 |
| PB Ratio | 3.30 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 10.26 |
| P/OCF Ratio | 9.11 |
| PEG Ratio | 1.00 |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 10.08, with an EV/FCF ratio of 14.02.
| EV / Earnings | 37.52 |
| EV / Sales | 2.74 |
| EV / EBITDA | 10.08 |
| EV / EBIT | 14.58 |
| EV / FCF | 14.02 |
Financial Position
The company has a current ratio of 2.95, with a Debt / Equity ratio of 1.54.
| Current Ratio | 2.95 |
| Quick Ratio | 1.64 |
| Debt / Equity | 1.54 |
| Debt / EBITDA | 3.38 |
| Debt / FCF | 4.70 |
| Interest Coverage | 9.49 |
Financial Efficiency
Return on equity (ROE) is 12.03% and return on invested capital (ROIC) is 10.73%.
| Return on Equity (ROE) | 12.03% |
| Return on Assets (ROA) | 6.46% |
| Return on Invested Capital (ROIC) | 10.73% |
| Return on Capital Employed (ROCE) | 11.85% |
| Weighted Average Cost of Capital (WACC) | 5.42% |
| Revenue Per Employee | $441,292 |
| Profits Per Employee | $32,189 |
| Employee Count | 3,023 |
| Asset Turnover | 0.55 |
| Inventory Turnover | 1.60 |
Taxes
In the past 12 months, Haemonetics has paid $30.72 million in taxes.
| Income Tax | 30.72M |
| Effective Tax Rate | 24.00% |
Stock Price Statistics
The stock price has decreased by -14.13% in the last 52 weeks. The beta is 0.53, so Haemonetics's price volatility has been lower than the market average.
| Beta (5Y) | 0.53 |
| 52-Week Price Change | -14.13% |
| 50-Day Moving Average | 58.05 |
| 200-Day Moving Average | 62.31 |
| Relative Strength Index (RSI) | 55.92 |
| Average Volume (20 Days) | 901,326 |
Short Selling Information
The latest short interest is 1.98 million, so 4.26% of the outstanding shares have been sold short.
| Short Interest | 1.98M |
| Short Previous Month | 2.07M |
| Short % of Shares Out | 4.26% |
| Short % of Float | 4.31% |
| Short Ratio (days to cover) | 3.34 |
Income Statement
In the last 12 months, Haemonetics had revenue of $1.33 billion and earned $97.31 million in profits. Earnings per share was $2.05.
| Revenue | 1.33B |
| Gross Profit | 796.58M |
| Operating Income | 250.40M |
| Pretax Income | 128.03M |
| Net Income | 97.31M |
| EBITDA | 362.11M |
| EBIT | 250.40M |
| Earnings Per Share (EPS) | $2.05 |
Full Income StatementBalance Sheet
The company has $245.44 million in cash and $1.22 billion in debt, with a net cash position of -$979.14 million or -$21.07 per share.
| Cash & Cash Equivalents | 245.44M |
| Total Debt | 1.22B |
| Net Cash | -979.14M |
| Net Cash Per Share | -$21.07 |
| Equity (Book Value) | 796.32M |
| Book Value Per Share | 17.23 |
| Working Capital | 552.28M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $293.22 million and capital expenditures -$32.78 million, giving a free cash flow of $260.44 million.
| Operating Cash Flow | 293.22M |
| Capital Expenditures | -32.78M |
| Depreciation & Amortization | 111.72M |
| Net Borrowing | -6.25M |
| Free Cash Flow | 260.44M |
| FCF Per Share | $5.60 |
Full Cash Flow StatementMargins
Gross margin is 59.71%, with operating and profit margins of 18.77% and 7.29%.
| Gross Margin | 59.71% |
| Operating Margin | 18.77% |
| Pretax Margin | 9.60% |
| Profit Margin | 7.29% |
| EBITDA Margin | 27.14% |
| EBIT Margin | 18.77% |
| FCF Margin | 19.52% |
Dividends & Yields
Haemonetics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 6.65% |
| Shareholder Yield | 6.65% |
| Earnings Yield | 3.64% |
| FCF Yield | 9.75% |
Analyst Forecast
The average price target for Haemonetics is $80.20, which is 34.65% higher than the current price. The consensus rating is "Buy".
| Price Target | $80.20 |
| Price Target Difference | 34.65% |
| Analyst Consensus | Buy |
| Analyst Count | 11 |
| Revenue Growth Forecast (5Y) | 5.82% |
| EPS Growth Forecast (5Y) | 39.83% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |
Stock Splits
The last stock split was on December 3, 2012. It was a forward split with a ratio of 2:1.
| Last Split Date | Dec 3, 2012 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 6 |
